Reach Us +44-3308187254


Dersleri yüzünden oldukça stresli bir ruh haline sikiş hikayeleri bürünüp özel matematik dersinden önce rahatlayabilmek için amatör pornolar kendisini yatak odasına kapatan genç adam telefonundan porno resimleri açtığı porno filmini keyifle seyir ederek yatağını mobil porno okşar ruh dinlendirici olduğunu iddia ettikleri özel sex resim bir masaj salonunda çalışan genç masör hem sağlık hem de huzur sikiş için gelip masaj yaptıracak olan kadını gördüğünde porn nutku tutulur tüm gün boyu seksi lezbiyenleri sikiş dikizleyerek onları en savunmasız anlarında fotoğraflayan azılı erkek lavaboya geçerek fotoğraflara bakıp koca yarağını keyifle okşamaya başlar
Unmet Needs And Challenges With Sustained Drug Delivery To The Eye | 23529
ISSN: 2167-065X

Clinical Pharmacology & Biopharmaceutics
Open Access

Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Unmet needs and challenges with sustained drug delivery to the eye

2nd International Summit on Clinical Pharmacy

Barbara M Wirostko

Accepted Abstracts: Clinic Pharmacol Biopharm

DOI: 10.4172/2167-065X.S1.008

Data confirm that many patients are unable to self-administer chronic eye drops effectively, including the arthritic aging population and uncooperative pediatric glaucoma patients. Patient videos and questionnaires have demonstrated the inability for patients to effectively self dose and administer the drops accurately and as prescribed. Recent data revealed that only 71% of 204 glaucoma patients were able to get a drop into the eye, and only 39% did so without touching the bottle to the surface of the eye. Such studies confirm eye drop wastage, potential contamination of the eye drop bottles, and poor understanding of the situation among participants. Furthermore, the current standard of care for Age Related Macular Degeneration has removed the patient from the equation, yet it is still time and resource intensive requiring roughly monthly in office intraocular injections over years. Thus an alternative delivery mode, with decreased frequency of administration and sustain release potential could 1) greatly improve local ocular and systemic safety and tolerability profiles by decreasing the amount of drug delivered locally, as well as 2) more effectively and efficiently manage ocular disease and resources by effectively targeting the disease and reducing patient visits. There are currently several novel and innovative sustained release (SR) delivery methods in various stages of development for both front of the eye (anterior segment and ocular surface) and back of the eye (intraocular retinal) pathologies. To develop a viable, reproducible, SR technology one must consider 1) formulation work; standardizing the release kinetics, and duration of action, 2) clinical study design and patient population (determining the timing of replacement or refill, and identifying the acceptable safety risk profile compared to the comparator), 3) encouraging physician and patient acceptance of perhaps a more invasive procedure, and 4) navigation of reimbursement issues to establish the rationale of a perhaps more costly product over the current comparator. This presentation will review some broad drug delivery platforms, the current landscape for treating ocular pathology with these SR delivery modes, will discuss what data are needed in development to allow such a novel technology to be a clinically viable marketed product, as well as the novel biodegradable polymer film being developed by my company Jade Therapeutics for anterior segment/ corneal pathology.
Barbara M Wirostko is co founder and Chief Scientific Officer of Jade Therapeutics Inc, an Ophthalmic drug delivery company located in Utah. Prior to founding Jade, She served as CMO of Altheos, a biotech company developing an NCE for glaucoma. A board certified ophthalmologist, she maintains an academic research and clinical practice with the University of Utah, Moran Eye Center, as a Clinical Adjunct Associate Professor in Ophthalmology. From 2006-2010she was Senior Medical Director within the Clinical Development Specialty division at Pfizer. She completed her glaucoma fellowship at Cornell University, and received her Ophthalmology training as well as her medical degree at Columbia University, College of Physicians and Surgeons, NY. She serves on the editorial board of Acta Ophthalmologic, various non-profit scientific advisory boards, and consults for companies focused on drug delivery including SKS Ocular. She is an active member and fellow of the AAO, ARVO, Women in Ophthalmology, and various local state societies.